21CTP.LEUK01 Site Feasibility Questionnaire v.1 |
Phase II Study of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Newly Diagnosed (Ph+) ALL
Your site is identified as a SWOG member, and we invite your participation in the SWOG Clinical Trial Partnership (CTP).
SWOG CTP is an independent, limited liability corporation with its own leadership, processes, and funding agreements. But the missions of SWOG and SWOG CTP are the same - to significantly improve lives through cancer clinical trials and translational research.
This clinical trial aims to assess the rate of major molecular remission in newly diagnosed patients with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia treated with a combination of Asciminib, Dasatinib, Prednisone, and Blinatumomab.
The following questionnaire aims to collect essential information about potential clinical trial sites to evaluate their suitability for the upcoming study. Please complete the summary by providing accurate and detailed responses to each section. Your input will greatly assist in assessing the feasibility of these sites and ensuring the successful execution of the study. Thank you for your participation in this site survey.
The following questionnaire aims to collect essential information about potential clinical trial sites to evaluate their suitability for the upcoming study. Please complete the summary by providing accurate and detailed responses to each section. Your input will greatly assist in assessing the feasibility of these sites and ensuring the successful execution of the study. Thank you for your participation in this site survey.